Skip Navigation


Annals of Oncology Advance Access originally published online on November 15, 2005
Annals of Oncology 2006 17(2):252-258; doi:10.1093/annonc/mdj060
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/2/252    most recent
mdj060v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pfeiffer, P.
Right arrow Articles by Glimelius, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfeiffer, P.
Right arrow Articles by Glimelius, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

P. Pfeiffer1,*, H. Sørbye2, H. Ehrsson3, T. Fokstuen4, J. P. Mortensen5, L. Baltesgard6, K. M. Tveit7, D. Øgreid8, H. Starkhammar9, I. Wallin3, C. Qvortrup1 and B. Glimelius4,10

1 Department of Oncology, Odense University Hospital, Odense, Denmark; 2 Department of Oncology, Haukeland University Hospital, Bergen, Norway; 3 Karolinska Pharmacy, Karolinska Hospital and Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden; 4 Department of Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; 5 Department of Oncology, Vejle Hospital, Vejle, Denmark; 6 Department of Oncology, Tromso University Hospital, Tromso, Norway; 7 Department of Oncology, Ullevaal University Hospital, Oslo, Norway; 8 Department of Oncology, Rogaland Central Hospital, Stavanger, Norway; 9 Department of Oncology, Linkoping University Hospital, Linkoping, Sweden; 10 Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden

* Correspondence to: Dr P. Pfeiffer, Department of Oncology, Odense University Hospital, Sdr Boulevard 29, DK – 5000 Odense C, Denmark. Tel: +45-65-41-15-90; Fax: +45-65-41-29-57; E-mail: per.pfeiffer{at}ouh.fyns-amt.dk

Background: The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established. Oxaliplatin induces acute, cold-induced neuropathy in most patients. The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended.

Patients and methods: For practical and economic reasons, but also for patient's convenience, we performed a phase II study to examine XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1–14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with ACRC resistant to irinotecan. In addition the pharmacokinetics of oxaliplatin was studied.

Results: From November 2002 to September 2003, 70 patients with ACRC were treated with XELOX30. Median age was 62 (range 33–74 years) years and median performance status was 1 (range 0–2). The median number of courses was four (range 1–12) and median cumulative dose of oxaliplatin was 530 (range 125–1560 ) mg/m2. The response rate was 17% (95% CI 10–23), median time to progression (TTP) was 5.4 months (95% CI 4.6–6.4) and median survival 9.5 months (95% CI 8.5–11.2). White blood cell count (WBC) and performance status were significantly correlated to TTP. Neurotoxicity was moderate: grade 1 56%, grade 2 17% and grade 3 6%. Other grade 3 toxicities were nausea/vomiting 9%, diarrhoea 14% and PPE 8%. The maximum blood concentration and total body clearance of oxaliplatin was higher than previously reported in studies examining 2-h infusions, but the volume of distribution and terminal half-life was in close agreement with previous results.

Conclusion: XELOX30 is a very convenient second-line regimen in ACRC with an activity and safety profile similar to other oxaliplatin schedules.

Key words: colorectal cancer, short-time infusion, pharmacokinetics, oxaliplatin, capecitabine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y.-J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, and D. Cunningham
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
Ann. Onc., October 1, 2008; 19(10): 1720 - 1726.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Qvortrup, M. Yilmaz, D. Ogreid, A. Berglund, L. Balteskard, J. Ploen, T. Fokstuen, H. Starkhammar, H. Sorbye, K. Tveit, et al.
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
Ann. Onc., June 1, 2008; 19(6): 1154 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Sorbye, C.-H. Kohne, D. J. Sargent, and B. Glimelius
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification
Ann. Onc., October 1, 2007; 18(10): 1666 - 1672.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.